- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04972708
Genetics of COVID-19 Risks & Resilience in Bipolar Disorder (BIPCOVID)
Genetics of COVID-19 Risks & Resilience in Bipolar Disorder as Subproject of BIPGEN (Genetic Changes in Bipolar Disorder)
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Methods: BIPGEN is a cross-sectional study on the genetics of bipolar disorder (BD). BIPGEN includes a personality questionnaire (TEMPS-A). DNA is isolated in the BIPGEN study from fasting blood with the QUIASYMPHONY robot from study participants with Bipolar Disorder (diagnosis according to DSM-IV) and healthy controls. The DNA is then genotyped with classic genotyping arrays (GWAS array). The aim of BIPGEN is to associate genetic variants (single-nucleotide-polymorphisms/ SNPs or copy-number-variations/CNVs) with bipolar affective disorder.
A subproject of BIPGEN is the BIP-COVID project, which is a cross-sectional genetics study about risks & resilience in the COVID-19 pandemic in BD and healthy controls at the Medical University of Graz. Study participants with BD and controls from the well-established BIPLONG and BIPGEN studies will undergo a special BIP-COVID visit, which will include a COVID-19 specific online Lime survey about the psychological burden in the COVID-19 crisis, a COVID-19 antibody test (IgM and IgG), inflammation markers and isolation of DNA from fasting blood. Genotyping of DNA will be done with the GSA V.3 array. Genetic analyses (Polygenic Risk Scores of I. Stress or Major Depression and II. COVID-19 infection established with the programs PLINK, PRSice and R) will be used to analyze the genetic mechanisms of COVID-19 pandemic associated psychological symptoms and COVID-19 infection risk. Systems biology methods will be used to depict protective pathways against COVID-19 infection (e.g. Lithium pathways) and against COVID-19 associated psychiatric symptoms
Aim:
- We aim at analyzing the neuropsychological and genetic underpinning of COVID-19 associatedreactive psychiatric symptoms in BD and in healthy controls.
- We aim at analyzing genetic predictors of COVID-19 infection in BD and in controls.
- We aim at analyzing the protective effects of the GSK-3β inhibitor lithium against COVID-19 infection.
Intervention: Cross-sectional genetics study
Key inclusion and exclusion criteria: Inclusion criteria are written consent after previous written and verbal information, diagnosis of BD according to DSM-IV and age between 18 and 75 years. Exclusion criteria include acute suicidality, lack of consent, severe active drug dependence (i.e., alcohol, benzodiazepines, morphine), other currently active severe mental / cerebral organic disease (e.g. epilepsy, brain tumor), severe skull-brain trauma / brain surgery in the past, known florid tumor disease, congenital / infantile mental retardation, dementia (from Mini-Mental State Examination (MMSE) 20), severe florid autoimmune diseases or current immunosuppression (e.g., lupus erythematosus, HIV (human immunodeficiency virus), multiple sclerosis), cardiac, renal and pulmonary disorders or PTSD (post-traumatic stress disorder) or anxiety.
Healthy controls do not have a history of mental disorder and do not have first- or second-degree relatives with psychiatric disorders.
Primary and secondary endpoint(s) of the BIPCOVID project:
The primary endpoint is PRS of stress, the secondary endpoint is PRS of COVID-19 risk.
Sample size, statistical analyses, power calculation: The program G*Power (Version 3.1) was used for the calculation of the number of cases. Linear bivariate regression analyses for two groups (BD and control cohort) will be calculated with the results from psychological/psychiatric inventories as predictors (e.g. Pittsburgh Sleep Quality Index, Mediterranean Diet Score, Resilience Scale) and the three PRS as criterion. G*Power calculates for a linear bivariate regression, with a Δ slope of 0.03, α = .05 and a power of 95 % a total sample size of 364 persons.
Trial duration of BIPCOVID: 3 years.
Participating centers: The BIP-COVID sample will be recruited as monocentric study at the special outpatient department for Bipolar Disorders (managed by Univ.Prof. Eva Reininghaus) at the Department of Psychiatry and Psychotherapeutic Medicine at the Medical University of Graz, Austria. Psychiatric genetics and bioinformatics experts from the University of Basel, the University of Marburg, the University of Bonn, the Karolinska Institutet & Medical University of Vienna & CAMH Toronto will supervise the KLIF-funded doctoral student and will support the state-of-the-art bioinformatics analyses.
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiekontakt
- Navn: Eva Reininghaus, MD, PhD, MBA
- Telefonnummer: +43 316 385 80968
- E-post: eva.reininghaus@medunigraz.at
Studiesteder
-
-
Styria
-
Graz, Styria, Østerrike, 8036
- Rekruttering
- Medical University Graz
-
Ta kontakt med:
- Eva Reininghaus, MD, PhD, MBA
- Telefonnummer: +43 316 385 80968
- E-post: eva.reininghaus@medunigraz.at
-
Ta kontakt med:
- Susanne Bengesser, MD, PhD, BSc
- Telefonnummer: +43 316 385 86224
- E-post: susanne.bengesser@medunigraz.at
-
Underetterforsker:
- Nina Dalkner, PhD
-
Underetterforsker:
- Susanne Bengesser, MD, PhD, BSc
-
Hovedetterforsker:
- Eva Reininghaus, MD, PhD, MBA
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Inclusion criteria are written consent after previous written and verbal information, diagnosis of BD according to DSM-IV and age between 18 and 75 years.
Exclusion Criteria:
Exclusion criteria include
- acute suicidality
- lack of consent
- severe active drug dependence (i.e., alcohol, benzodiazepines, morphine)
- other currently active severe mental / cerebral organic disease (e.g. epilepsy, brain tumor),
- severe skull-brain trauma / brain surgery in the past,
- known florid tumor disease,
- congenital / infantile mental retardation,
- dementia (from MMSE 20),
- severe florid autoimmune diseases or current immunosuppression (e.g., lupus erythematosus, HIV, multiple sclerosis),
- cardiac, renal and pulmonary disorders or PTSD or anxiety
- Healthy controls do not have a history of mental disorder and do not have first- or second-degree relatives with psychiatric disorders.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
- Tidsperspektiver: Potensielle
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
Bipolar Disorder
100 patients after COVID-19 infection 100 patients without COVID-19 infection
|
Cross-sectional genetics study
|
Healthy controls
100 controls after COVID-19 infection 100 controls without COVID-19 infection
|
Cross-sectional genetics study
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
PRS of stress or depression
Tidsramme: 3 Years
|
genetic sum score for depression (polygenic risk score)- the higher the score, the higher the risk
|
3 Years
|
PRS of COVID-19 infection
Tidsramme: 3 Years
|
genetic sum score for COVID-19 infection (polygenic risk score)- the higher the score, the higher the risk
|
3 Years
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Psykiske lidelser
- Patologiske prosesser
- Coronavirus-infeksjoner
- Coronaviridae-infeksjoner
- Nidovirales infeksjoner
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Luftveisinfeksjoner
- Sykdommer i luftveiene
- Lungebetennelse, viral
- Lungebetennelse
- Lungesykdommer
- Bipolare og relaterte lidelser
- Covid-19
- Sykdom
- Bipolar lidelse
Andre studie-ID-numre
- 23-199 ex 10/11
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Covid-19
-
HealthQuiltFullførtImmunfunksjon | Covid19 positiv pasient | Covid19 nærkontaktForente stater
-
VA Office of Research and DevelopmentAktiv, ikke rekrutterendeKOLS-pasienter og pasienter som kommer seg etter COVID19Forente stater
-
Bahçeşehir UniversityFullførtLang Covid19 | Autonom dysfunksjonTyrkia
-
Ohio State UniversityRekrutteringPost-akutt COVID19-syndrom | Lang COVID | Tilstand etter COVID19Forente stater
-
Texas Woman's UniversityNational Institutes of Health (NIH)Har ikke rekruttert ennå
-
Aarhus University HospitalUniversity of Aarhus; Pharma NordFullført
-
Cairo UniversityKasr El Aini HospitalUkjentCOVID19 lungebetennelseEgypt
-
Assistance Publique - Hôpitaux de ParisUkjent
-
Saglik Bilimleri Universitesi Gazi Yasargil Training...FullførtCovid19 og dødelighetTyrkia
-
Brugmann University HospitalRekruttering